Table 3.
Other treatment modalities
| Study | Design | N | Mean age | Male (%) | HIV-positive (%) | MSM (%) | High-gradeAIN (%) | Treatmentlength | CR (%) | PR (%) | Recurred (%) | ASCC (%) | Follow-up (median in months) | Level of evidence | Bias score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical excision | |||||||||||||||
| Scholefieldet al. 1994[41] | Retrospective chartreview | 27 | 45 | - | - | - | 100 | - | - | - | 30 | 11 | 20 (mean) | 4 | Critical + |
| Brown et al.1999 [23] | Retrospective chartreview | 34 | 44 | - | - | - | 100 | - | - | 18 | - | 41 | 4 | Critical + | |
| N = 61 | |||||||||||||||
| Photodynamic therapy | |||||||||||||||
| Van de Snoeket al. 2012 [39] | Prospective open-label pilot study | 15 | 46 | 100 | 100 | 100 | 100 | 1 systemictreatment | 20 | 27 | 20 | 0 | - | 4 | Serious + |
| Welbournet al. 2011[40] | Retrospective chartreview | 15 | 52 | 47 | - | - | - | 1 systemic ortopicaltreatment | 40 | 20 | 20 | 0 | 19 | 4 | Serious + |
| N = 30 | |||||||||||||||
| HPV vaccination | |||||||||||||||
| Swedishet al. 2012[42] | Prospective cohort | 202 | 40 | 100 | 0 | 100 | 100 | 3 doses ofquadrivalentHPVvaccination | - | - |
13vaccinated 31unvaccinated |
0 |
60 unvaccinated 41 vaccinated |
2B | Moderate + |
| Wilkin et al.2018 [43] | Double-blindRandomisedControlled Trial | 575 |
47 vaccinated 48 placebo |
82 | 100 | - | 67 | 3 doses ofquadrivalentHPVvaccination | - | - |
16vaccinated 16placebo |
0 | 41 | 1C | Low* |
| Palefskyet al. 2006[44] | Phase 1 + 2 trial ofexperimentalHPV vaccineSGN00101 | 15 | 48 | 87 | 100 | - | 100 | 3 doses ofexperimentalHPV vaccineSGN00101 | 7 | 27 | 0 | 0 | 11 | 2B | High* |
| N = 31 | |||||||||||||||
+ Robins I tool* Cochrane risk of bias tool